Grifols is a leveraged but strategically valuable plasma-therapy turnaround where deleveraging, margin recovery, and a potential U.S. Biopharma IPO could unlock substantial upside.
Overview
Grifols is a global plasma-derived therapies leader with Biopharma generating more than 85% of revenue. Its vertically integrated U.S. plasma network, differentiated therapies such as Gamunex and Xembify, and long-standing clinical reputation support durable demand. Revenue is heavily U.S.-weighted, while customers include hospitals, healthcare systems, labs, blood agencies, and public health bodies. The core attraction is a defensive, recurring healthcare business, but investor confidence depends on margin recovery, deleveraging, and resolving governance concerns.